1. Introduction {#s0005}
===============

The current article presents the preclinical pharmacology of marine natural products during 2007--8 maintaining the format used in the previous reviews ([@bb0680], [@bb0665], [@bb0670], [@bb0675], [@bb0690], [@bb0695]). The preclinical pharmacology of antitumor and cytotoxic marine compounds has been reported in separate reviews ([@bb0640], [@bb0685], [@bb0655], [@bb0660], [@bb0645], [@bb0650]). We have restricted the current as well as previous reviews to peer-reviewed articles reporting the bioactivity or pharmacology of structurally characterized marine compounds. As we have done previously, we have continued to use a modification of Schmitz\'s chemical classification ([@bb0865]) to assign marine natural product structures to six major chemical classes, namely, polyketides, terpenes, peptides, alkaloids, shikimates, and sugars. Novel antibacterial, anticoagulant, antifungal, antimalarial, antiprotozoal, antituberculosis and antiviral preclinical pharmacology of marine metabolites are presented in [Table 1](#t0005){ref-type="table"} with the corresponding structures shown in [Fig. 1](#f0005){ref-type="fig"} . Marine compounds that affect the immune and nervous systems, as well as those with anti-inflammatory effects are grouped in [Table 2](#t0010){ref-type="table"} , with their corresponding structures presented in [Fig. 2](#f0010){ref-type="fig"} . Finally, marine compounds that have been demonstrated to affect a variety of cellular and molecular targets are exhibited in [Table 3](#t0015){ref-type="table"} , and their structures depicted in [Fig. 3](#f0015){ref-type="fig"} . Several articles were published during 2007--8 reporting the preclinical pharmacology of extracts or structurally uncharacterized marine compounds, and although these have not been included in the present review, they probably may warrant further investigation: antimicrobial effects of the Turkish red alga *Jania rubens* ([@bb0415]); antimicrobial activity in Portuguese marine cyanobacteria *Synechocystis* sp. and *Synechococcus* sp. extracts towards Gram-positive bacteria ([@bb0620]); antibacterial activity against human and fish bacteria from the sub-Arctic colonial ascidian *Synoicum pulmonaria* from northern Norway ([@bb0900]); strong antibiotic-producing potential in actinomycetes from sediments in the Trondheim fjord in Norway ([@bb0095]); antibacterial activity of deep-sea bacteria from sediments of the West Pacific Ocean ([@bb1005]); potent antimicrobial activity in the green alga *Enteromorpha intestinalis* collected in Gujarat, India ([@bb0730]); a nonhemolytic antimicrobial lipopeptide derived from the marine bacterium *Bacillus circulans* ([@bb0185]); a T-antigen binding lectin with bioactivity against a broad spectrum of Gram-positive and Gram-negative bacteria from the sea cucumber *Holothuria scabra* ([@bb0285]); anticoagulant activity of a 100--500 kDa polysaccharide isolated from the fermented red seaweed *Lomentaria catenata* which was greater than the clinical anticoagulant heparin ([@bb0820]); antimycobacterial activity in long-chain fatty acids isolated from the red alga *Polysiphonia virgata* ([@bb0860]); antileishmanial and anti-trichomonal activity in organic extracts of several Mexican red and brown algae ([@bb0270], [@bb0715]); anti-HIV-1 activity of novel sulfated galactans isolated from the Chinese red algae *Grateloupia longifolia* and *Grateloupia filicina* ([@bb0950], [@bb0955]); significant anti-herpes simplex virus activity in a 30 kDa polysaccharide isolated from the red alga *Gracilaria corticata* ([@bb0130]); immunomodulatory effects of an enzymatic extract from the South Korean marine brown alga *Ecklonia cava* on murine splenocytes ([@bb0020]); immunostimulant properties of a sulfated polysaccharide isolated from the Brazilian red alga *Champia feldmannii* ([@bb0045]); antioxidant and antimicrobial activity of the Indian red and brown seaweed methanolic extracts with high phenolic contents ([@bb0205]); and decreased expression of key regulatory genes involved in cholesterol and fatty acid biosynthetic pathways by the lipid extract of the cyanobacterium *Nostoc commune* var. *sphaeroides* Kützing ([@bb0825]).Table 1Marine pharmacology in 2007--8: marine compounds with antibacterial, anticoagulant, antifungal, antimalarial, antiprotozoal, antituberculosis, and antiviral activities.Drug classCompound**/**organism^a^ChemistryPharmacologic activityIC~50~^b^MMOA^b^Country^c^ReferencesAntibacterialAscochytatin ([1](#p0010){ref-type="p"})/fungusPolyketide^d^*B. subtilis* inhibition0.3 μg^++^TCS (YycG and YycF) regulatory systemJPN([@bb0410])Antibacterial[L]{.smallcaps}-Amino acid oxidase SSAP ([2](#p0010){ref-type="p"})/rockfishProtein^f^*A. salmonicida*, *P. damselae* subsp. *piscida* and *V. parahaemolyticus* inhibition0.078--0.63 μg/mL^+^H~2~O~2~ mediates the antibacterial actionJPN([@bb0455])AntibacterialArenicin-1 ([3](#p0010){ref-type="p"})/polychaetePeptide^f^*P. aeruginosa* and *S. aureus* inhibition2 μg/mL^+^Binding and disruption of cell membraneS. KOR([@bb0530], [@bb0535])AntibacterialIsoaaptamine ([4](#p0010){ref-type="p"})/spongeAlkaloid^f^*S. aureus* inhibition3.7 μg/mLSortase A inhibition and fibronectin bindingS. KOR([@bb0380])Antibacterial*Dysidea* sp. Sesterterpenes ([5](#p0010){ref-type="p"}, [6](#p0010){ref-type="p"}, [7](#p0010){ref-type="p"}, [8](#p0010){ref-type="p"}, [9](#p0010){ref-type="p"}, [10](#p0010){ref-type="p"}, [11](#p0010){ref-type="p"}) /spongeTerpenoid^e^*B. subtilis* inhibition1.56--12.5 μg/mL^+^Isocitrate lyase inhibitionS. KOR([@bb0540])AntibacterialSulfoalkylresorcinol ([12](#p0010){ref-type="p"})/fungusPolyketide^d^Methicillin-resistant *S. aureus* inhibition12.5 μg/mL^+^FtsZ polymerization inhibitionJPN([@bb0405])AntibacterialAmbiguines H and I ([13](#p0010){ref-type="p"}, [14](#p0010){ref-type="p"})/bacteriumAlkaloid^f^*S. albus* and *B. subtilis* inhibition0.08--1.25 μg/mL^+^UndeterminedISR([@bb0830])AntibacterialAriakemicins A and B ([15](#p0010){ref-type="p"}, [16](#p0010){ref-type="p"})/bacteriumPolyketide^d^*S. aureus* inhibition0.46 μg^++^UndeterminedJPN([@bb0765])AntibacterialAyamycin ([17](#p0010){ref-type="p"})/bacteriumPolyketide^d^Gram-positive and -negative bacteria inhibition0.1 μg/mL^+^UndeterminedEGY, GBR([@bb0235])AntibacterialBatzelladine L and M ([18](#p0010){ref-type="p"}, [19](#p0010){ref-type="p"})/spongeAlkaloid^f^*S. aureus* and methicillin-resistant *S. aureus* inhibition0.25--5.0 μg/mL^+^UndeterminedUSA, CHN, ESP, NZL([@bb0340])Antibacterial*L. herbacea* diphenyl ether ([20](#p0010){ref-type="p"})/spongePolyketide^d^*B. subtilis* inhibition0.1 μg^++^UndeterminedJPN, IDN, NLD([@bb0320])AntibacterialEssramycin ([21](#p0010){ref-type="p"})*/*bacteriumAlkaloid^f^*B. subtilis*, *S. aureus* and *M. luteus* inhibition1--85 μg/mL^+^UndeterminedEGY, DEU([@bb0240])Antibacterial(+)-Isojaspic acid ([22](#p0010){ref-type="p"})/spongeTerpenoid^e^*S. epidermis* inhibition2.5 μg/mL^+^UndeterminedUSA, NLD([@bb0840])AntibacterialLynamicins A--D ([23](#p0010){ref-type="p"}, [24](#p0010){ref-type="p"}, [25](#p0010){ref-type="p"}, [26](#p0010){ref-type="p"})/bacteriumAlkaloid^f^Methicillin-resistant *S. aureus* inhibition1.8--9.5 μg/mL^+^UndeterminedUSA([@bb0705])AntibacterialLipoxazolidinones A and B ([27](#p0010){ref-type="p"}, [28](#p0010){ref-type="p"})/bacteriumPolyketide^d^*Staphylococcus* sp., *S. pneumoniae*, *E. faecalis* inhibition0.5--16 μg/mL^+^UndeterminedUSA([@bb0595])AntibacterialMarinopyrrole A ([29](#p0010){ref-type="p"})/bacteriumAlkaloid^f^Methicillin-resistant *S. aureus* inhibition0.31 μM^+++^UndeterminedUSA([@bb0350])Antibacterial(--)-Microcionin-1 ([30](#p0010){ref-type="p"})/spongeTerpenoid^e^*M. luteus* inhibition6 μg/mL^+^UndeterminedPRT, ESP([@bb0280])AntibacterialPhomolide B ([31](#p0010){ref-type="p"})/fungusPolyketide^d^*E. coli* inhibition5--10 μg/mL^+^UndeterminedCHN([@bb0210])AntibacterialSargaquinoic acid derivative ([32](#p0010){ref-type="p"})/algaTerpenoid^e^*S. aureus* inhibition2 μg/mL^+^UndeterminedJPN([@bb0335])AntibacterialTauramamide ([33](#p0010){ref-type="p"})/bacteriumPeptide^f^*Enterococcus* sp*.* inhibition0.1 μg/mL^+^UndeterminedCAN, PAP, USA([@bb0200])AnticoagulantAnticoagulant polypeptide (TGAP) ([34](#p0010){ref-type="p"})/bivalveProtein^f^Inhibition of factor II- to IIa conversion77.9 nMSpecific binding to factor Va and factor IIS. KOR([@bb0395])Antifungal*Odonthalia corymbifera* bromophenols ([35](#p0010){ref-type="p"}, [36](#p0010){ref-type="p"}, [37](#p0010){ref-type="p"})/algaPolyketide^d^*Magnaporthe grisea* inhibition2.0--2.8 μMIsocitrate lyase inhibitionS. KOR([@bb0530], [@bb0535])AntifungalCallipeltins J and K ([38](#p0010){ref-type="p"}, [39](#p0010){ref-type="p"})/spongePeptide^f^*C. albicans* inhibition1 μM^+^UndeterminedITA, FRA([@bb0175])AntifungalHolothurin B ([40](#p0010){ref-type="p"})/sea cucumberTriterpenoid glycoside^e^*T. mentagrophytes* and *S. schenckii* inhibition1.56 μg/mL^+^UndeterminedIND([@bb0495])AntifungalNeopeltolide ([41](#p0010){ref-type="p"})/spongePolyketide^d^*C. albicans* inhibition0.62 μg/mL^+^UndeterminedUSA([@bb0995])AntifungalPedein A ([42](#p0010){ref-type="p"})/bacteriumPeptide^f^*R. glutinis*, *S. cerevisae* and *C. albicans*0.6--1.6 μg/mL^+^UndeterminedDEU([@bb0500])AntifungalPseudoceratins A and B ([43](#p0010){ref-type="p"}, [44](#p0010){ref-type="p"})/spongePKS/NRPS^f^*C. albicans* and mutant *S. cerevisae* inhibition6.5--8.0 μg^++^UndeterminedJPN([@bb0375])Antimalarial(*E*)-Oroidin ([45](#p0010){ref-type="p"}) and (*E*)-oroidin TFA salt ([46](#p0010){ref-type="p"})/spongeAlkaloid^f^*P. falciparum* K1 strain inhibition3.9--7.9 μg/mLFabI inhibitionCHE, GBR, USA, TUR([@bb0925])AntimalarialDragomabin ([47](#p0010){ref-type="p"})/bacteriumPeptide^f^*P. falciparum* W2 strain inhibition6.0 μMUndeterminedPAN, USA([@bb0710])AntimalarialVenturamides A and B ([48](#p0010){ref-type="p"}, [49](#p0010){ref-type="p"})/bacteriumPeptide^f^*P. falciparum* W2 strain inhibition5.6--8.2 μMUndeterminedPAN, USA([@bb0570])AntimalarialNodulisporacid A ([50](#p0010){ref-type="p"})/fungusPolyketide^d^*P. falciparum* 94 strain inhibition1--10 μMUndeterminedTHAI([@bb0420])Antimalarial*Streptomyces* sp. H668 polyether ([51](#p0010){ref-type="p"})/bacteriumPolyketide^d^*P. falciparum* D6 and W2 strain inhibition0.1--0.2 μg/mLUndeterminedS. KOR, USA([@bb0720])AntimalarialTumonoic acid I ([52](#p0010){ref-type="p"})/bacteriumPolyketide^d^*P. falciparum* D6 and W2 strain inhibition2 μMUndeterminedPAP, USA([@bb0155])AntimalarialChaetoxanthone B ([53](#p0010){ref-type="p"})/fungusPolyketide^d^*P. falciparum* K1 strain inhibition0.5 μg/mLUndeterminedCHE([@bb0810])AntiprotozoalPlakortide P ([54](#p0010){ref-type="p"})/spongePolyketide^e^Inhibition of *L. chagasi* and *T. cruzi*0.5--2.3 μg/mLUndetermined, though not involving nitric oxideBRA([@bb0480])AntiprotozoalViridamides A and B ([55](#p0010){ref-type="p"}, [56](#p0010){ref-type="p"})/bacteriumPeptide^f^Inhibition of *L. mexicana* and *T. cruzi*1.1--1.5 μMUndeterminedPAN, USA([@bb0885])AntiprotozoalChaetoxanthone B ([53](#p0010){ref-type="p"})/fungusPolyketide^d^*T. cruzi* Tulahuen C4 strain inhibition1.5 μg/mLUndeterminedCHE([@bb0810])AntituberculosisBipinnapterolide B ([57](#p0010){ref-type="p"})/coralTerpenoid^e^*M. tuberculosis* inhibition128 μg/mL^⁎^UndeterminedUSA([@bb0770])Antituberculosis8′-*O-*Demethylnigerone ([58](#p0010){ref-type="p"}) and 8′-*O-*demethylisonigerone ([59](#p0010){ref-type="p"})/fungusPolyketide^d^*M. tuberculosis* inhibition21.5 and 43.0 μMUndeterminedCHN([@bb1025], [@bb1030])AntituberculosisCaribenols A and B ([60](#p0010){ref-type="p"}, [61](#p0010){ref-type="p"})/soft coralTerpenoid^e^*M. tuberculosis* inhibition63 and 128 μg/mL^+^UndeterminedUSA([@bb0965], [@bb0970])AntituberculosisParguesterols A and B ([62](#p0010){ref-type="p"}, [63](#p0010){ref-type="p"})/spongeTriterpenoid^f^*M. tuberculosis* inhibition7.8 and 11.2 μg/mL^+^UndeterminedUSA([@bb0965], [@bb0970])AntituberculosisSpiculoic acids ([64](#p0010){ref-type="p"}, [65](#p0010){ref-type="p"}, [66](#p0010){ref-type="p"})/spongePolyketide^d^*M. tuberculosis* inhibition50 μg/mL^+++^UndeterminedESP, FRA([@bb0065])AntiviralEsculetin ethyl ester ([67](#p0010){ref-type="p"})/spongePolyketide^d^SARS-Corona virus viral protease 3CL inhibition46 μMUndeterminedBRA, CAN([@bb0190])Antiviral*Cryptonemia crenulata* galactan ([68](#p0010){ref-type="p"})/algaPolysaccharide^g^Dengue type 2 inhibition0.8--16 μg/mLInhibition of viral binding and cell penetrationARG, BRA([@bb0905])Antiviral6,6′-Bieckol ([69](#p0010){ref-type="p"})/algaShikimateInhibition of HIV-1 infection1.07--1.72 μMViral p24 antigen production and reverse transcriptase inhibitionCHN, S. KOR([@bb0040])AntiviralDolabelladienetriol ([70](#p0010){ref-type="p"})*/*algaTerpenoid^e^Inhibition of HIV-1 replication8.4 μMNoncompetitive inhibition of reverse transcriptaseBRA([@bb0150])AntiviralMirabamides A, C and D ([71](#p0010){ref-type="p"}, [72](#p0010){ref-type="p"}, [73](#p0010){ref-type="p"})/spongePeptide^f^Inhibition of HIV-1 fusion0.041--3.9 μMInteraction with HIV-1 envelope glycoproteinsNZL, USA([@bb0795])AntiviralSulfated SPMG ([74](#p0010){ref-type="p"})/algaPolysaccharide^g^Inhibition of HIV-1 infectionInhibition of HIV-1 Tat-induced angiogenesisCHN([@bb0585])[^1]Fig. 1Marine compounds with antibacterial, anticoagulant, antifungal, antimalarial, antiprotozoal, antituberculosis, and antiviral activities.Table 2Marine pharmacology in 2007--8: marine compounds with anti-inflammatory activity, and affecting the immune and nervous systems.Drug classCompound**/**organism^a^ChemistryPharmacological activityIC~50~^b^MMOA^c^Country^d^ReferencesAnti-inflammatoryAscidiathiazones A ([75](#p0010){ref-type="p"}) and B ([76](#p0010){ref-type="p"})/ascidianAlkaloid^g^Human neutrophil free radical inhibition *in vitro* and *in vivo*0.44--1.55 μMSuperoxide anion inhibitionNZL([@bb0780])Anti-inflammatoryCrassumolides A and C ([77](#p0110){ref-type="p"}, [78](#p0110){ref-type="p"})/soft coralTerpenoid^e^Modulation of LPS-activated murine macrophage cell line\< 10 μMInducible NOS and COX-2 inhibitionTAIW([@bb0125])Anti-inflammatoryDurumolides A-C ([79](#p0110){ref-type="p"}, [80](#p0110){ref-type="p"}, [81](#p0110){ref-type="p"})/soft coralTerpenoid^e^Modulation of LPS-activated murine macrophage cell line\< 10 μMInducible NOS and COX-2 inhibitionTAIW([@bb0135])Anti-inflammatoryFrajunolides B and C ([82](#p0110){ref-type="p"}, [83](#p0110){ref-type="p"})/coralTerpenoid^e^Human neutrophil free radical inhibition *in vitro*\> 10 μg/mL^⁎^Superoxide anion and elastase inhibitionTAIW([@bb0875])Anti-inflammatory*Gracilaria verrucosa* fatty acids ([84](#p0110){ref-type="p"}, [85](#p0110){ref-type="p"})/algaPolyketide^d^Modulation of LPS-activated murine macrophages *in vitro*\< 20 μg/mL^⁎^NO, IL-6 and TNF-α inhibitionS. KOR([@bb0180])Anti-inflammatory*Hypnea cervicornis* lectin ([86](#p0010){ref-type="p"})/algaPeptide^g^Antinociception and anti-inflammatory effects *in vivo*0.1--1 mg/kg^⁎^Carbohydrate-binding site interactionBRA([@bb0075])Anti-inflammatoryManzamine (MZA) ([87](#p0010){ref-type="p"}), (--)-8-hydroxy MZA ([88](#p0010){ref-type="p"}), hexahydro-8-hydroxy MZA ([89](#p0110){ref-type="p"})/spongeAlkaloid^g^Modulation of LPS-activated brain microglia *in vitro*0.25--1.97 μMTXB~2~ inhibitionUSA([@bb0225])Anti-inflammatoryω-3 PUFA ([90](#p0110){ref-type="p"}, [91](#p0110){ref-type="p"}, [92](#p0110){ref-type="p"}, [93](#p0110){ref-type="p"})/musselPolyketide^d^Human neutrophil lipoxygenase inhibition *in vitro*NDLTB4 and 5-HETE inhibitionAUS([@bb0930])Anti-inflammatory*Perithalia capillaris* quinone ([94](#p0110){ref-type="p"})/algaShikimateHuman neutrophil free radical release inhibition *in vitro*2.1 μMSuperoxide anion inhibitionNZL([@bb0855])Anti-inflammatoryPFF-B ([95](#p0110){ref-type="p"})/algaPolyketide^d^Rat basophilic leukemia cell histamine release inhibition7.8 μMInhibition of β-hexosaminidase releaseJPN([@bb0890])Anti-inflammatoryPlakortide P ([54](#p0010){ref-type="p"})/spongePolyketide^e^Modulation of LPS-activated brain microglia *in vitro*0.93 μMTXB~2~ inhibitionBRA([@bb0480])Anti-inflammatoryRubrolide O ([96](#p0110){ref-type="p"})/ascidianPolyketide^d^Human neutrophil free radical release inhibition *in vitro*35 μMSuperoxide anion inhibitionNZL([@bb0785])Anti-inflammatoryStearidonic ([97](#p0110){ref-type="p"})/algaPolyketide^d^Inhibition of mouse ear inflammation160--314 μg/earInhibition of edema, erythema and blood flowS. KOR, JPN([@bb0430])Anti-inflammatoryCarteramine A ([98](#p0110){ref-type="p"})/spongeAlkaloid^g^Neutrophil chemotaxis inhibition5 μMUndeterminedJPN([@bb0465])Anti-inflammatoryLyngbyastatins 5--7 ([99](#p0110){ref-type="p"}, [100](#p0110){ref-type="p"}, [101](#p0110){ref-type="p"})/bacteriumPeptide^g^Elastase inhibition3--10 nMUndeterminedUSA([@bb0915])Anti-inflammatorySalinipyrone A ([102](#p0110){ref-type="p"})/bacteriumPolyketide^e^Mouse splenocyte interleukin-5 inhibition10 μg/mLUndeterminedUSA([@bb0760])Immune systemCycloprodigiosin hydrochloride ([103](#p0110){ref-type="p"})/bacteriumAlkaloid^g^Interleukin-8 inhibition1 μMAP-1 transcription factor inhibitionJPN([@bb0425])Immune systemFloridoside ([104](#p0110){ref-type="p"})/algaSugar^h^Activation of classical complement pathway5.9--9.3 μg/mL^⁎^IgM mediated-effectFRA([@bb0165])Immune systemIantherans ([105](#p0110){ref-type="p"}, [106](#p0110){ref-type="p"})/spongePolyketide^d^Activation of Ca^2+^-mobilization0.48--1.3 μMIonotropic P2Y~11~ receptor activationDEU, USA([@bb0290])Immune systemProdigiosin ([107](#p0110){ref-type="p"})/bacteriumAlkaloid^g^Macrophage iNOS inhibition0.1 μg/mL^⁎^NF-κB transcription factor inhibitionS. KOR([@bb0355])Immune systemASLP ([108](#p0110){ref-type="p"})/clamPolysaccharide^h^Splenocyte proliferation increase\< 100 μg/mL^⁎^UndeterminedCHN([@bb0325])Immune systemFrondoside A ([109](#p0110){ref-type="p"})/sea cucumberTerpenoid glycosideLysosomal activity, phagocytosis and ROS activation0.1--0.001 μg/mLUndeterminedRUS, USA([@bb0030])Immune system*Hippospongia* sp. quinones ([110](#p0110){ref-type="p"}, [111](#p0110){ref-type="p"}, [112](#p0110){ref-type="p"})/spongeTerpenoid^f^Enhancement of IL-8 release\> 1 μg/mL^⁎^UndeterminedJPN([@bb0750])Immune systemMacrosphelide M ([113](#p0110){ref-type="p"})/fungusPolyketide^d^Cell adhesion inhibition33.2 μMUndeterminedJPN([@bb1010])Immune systemPeribysin J ([114](#p0110){ref-type="p"})/fungusTerpenoid^f^Cell adhesion inhibition11.8 μMUndeterminedJPN([@bb1010])Immune systemQuerciformolide C ([115](#p0110){ref-type="p"})/soft coralTerpenoid^f^Macrophage iNOS and COX-2 inhibition\< 10 μM^⁎^UndeterminedTAIW([@bb0590])Immune system*Spongia* sp. diterpenoids ([116](#p0110){ref-type="p"}, [117](#p0110){ref-type="p"})/spongeTerpenoid^f^Murine spleen cell lysosome activation\> 100 μg/mL^⁎^UndeterminedRUS([@bb0805])Immune systemThalassospiramide B ([118](#p0110){ref-type="p"})/bacteriumPeptide^g^Interleukin 5 inhibition5 μMUndeterminedUSA([@bb0755])Nervous systemLinckosides L1 and L2 ([119](#p0110){ref-type="p"}, [120](#p0110){ref-type="p"})/sea starTriterpenoid glycoside^f^Induction of neurite outgrowth0.3 μM^⁎^UndeterminedITA, RUS([@bb0440])Nervous systemLinckosides M--Q ([121](#p0110){ref-type="p"}, [122](#p0110){ref-type="p"}, [123](#p0110){ref-type="p"}, [124](#p0110){ref-type="p"}, [125](#p0110){ref-type="p"})/sea starTriterpene^f^Induction of neurite outgrowth\< 10 μM^⁎^Dependent on xylose on side chainJPN([@bb0315])Nervous systemPhaeophytin A ([126](#p0110){ref-type="p"})/algaAlkaloid/terpenoidInduction of neurite outgrowth\< 3.9 μM^⁎^MAP kinase activationJPN([@bb0365])Nervous system*Conus leopardus* conotoxin Lp1.1 ([127](#p0110){ref-type="p"})/snailPeptide^g^Seizure and paralysis in goldfish\< 10 μM^⁎^Slow block of α6α3β2 and α3β2 nicotinic receptorCHN, USA([@bb0790])Nervous systemDamipipecolin ([128](#p0110){ref-type="p"}) and damituricin ([129](#p0110){ref-type="p"})/spongeAlkaloid^g^Inhibition of serotonin receptor binding1 μg/mL^⁎^Ca^2+^ influx inhibitionITA, DEU([@bb0025])Nervous system4-Acetoxy-plakinamine B ([130](#p0110){ref-type="p"})/spongeTriterpenoid alkaloid^g^Acetylcholinesterase inhibition3.75 μMMixed-competitive inhibitionTHAI([@bb0525])Nervous systemSargaquinoic acid ([131](#p0110){ref-type="p"}) and sargachromenol ([132](#p0110){ref-type="p"})/algaTerpenoid^f^Butyrylcholinesterase inhibition26 nMUndeterminedS. KOR([@bb0140])Nervous systemSPMG ([74](#p0010){ref-type="p"})/algaPolysaccharide^h^Neuronal Ca^2+^-apoptosis inhibitionDecrease in caspase-3 activityCHN([@bb0360])[^2]Fig. 2Marine compounds with anti-inflammatory activity, and affecting the immune and nervous systems.Table 3Marine pharmacology in 2007--8: marine compounds with miscellaneous mechanisms of action.Compound/organism^a^ChemistryPharmacological activityIC~50~^b^MMOA^c^Country^d^ReferencesAzumamide E ([133](#p0110){ref-type="p"})/spongePeptide^g^Histone deacetylase inhibition50--80 nMSelective inhibition of isoforms 1, 2, and 3ITA([@bb0635])1-Deoxyrubralactone ([134](#p0110){ref-type="p"})/fungusShikimateX and Y DNA polymerase inhibition12--60 μMSpecific inhibition of DNA polymerase β and κJPN([@bb0725])Fucoxanthin ([135](#p0110){ref-type="p"})/algaCarotenoidAntioxidant *in vitro*0.14--2.5 mg/mLHydroxyl and superoxide radical scavengingJPN([@bb0845])Okadaic acid ([136](#p0110){ref-type="p"})/spongePolyketide^e^Protein phosphatase 1 and 2A inhibition0.96 nM^⁎⁎^Okadaic acid binding to proteins OABP1 and OABP2JPN([@bb0895])Saproxanthin ([137](#p0110){ref-type="p"}) and myxol ([138](#p0110){ref-type="p"})/bacteriumPolyketide^e^[l]{.smallcaps}-Glutamate toxicity inhibition3.1--8.1 μMLipid peroxidation inhibitionJPN([@bb0880]a)Sarcomilasterol ([139](#p0110){ref-type="p"})/spongeTriterpene^f^Osteoblast growth stimulation3 μMAlkaline phosphatase elevationS. KOR, VNM([@bb0945])Spirastrellolides C, D, and E ([140](#p0155){ref-type="p"}, [141](#p0155){ref-type="p"}, [142](#p0155){ref-type="p"})/spongePolyketide^e^Premature mitosis inhibition0.4--0.7 μMProtein phosphatase 2A inhibitionCAN([@bb0980], [@bb0985])*Spongia* sesterterpenoid ([143](#p0110){ref-type="p"})/spongeTerpenoid^f^Hypercholesterolemia antagonist2.4 μMFarnesoid X-activated receptor coactivator peptide inhibitionS. KOR([@bb0740])Stylissadines A and B ([144](#p0155){ref-type="p"}, [145](#p0155){ref-type="p"})/spongeAlkaloid^g^Reduction of voltage-dependent Ca^2+^ entry4.5 μMIrreversible effect requiring lipophilic brominated side chainDEU([@bb0070])Symbiodinolide ([146](#p0110){ref-type="p"})/dinoflagellatePolyketide^e^Voltage-dependent N-type Ca^2+^ channel activation7 nMCyclooxygenase 1 inhibitionJPN([@bb0445])*Asterias amurensis* saponin ([147](#p0110){ref-type="p"})/starfishTriterpene^f^Osteoblast cell proliferation50 μM^⁎^UndeterminedCHN([@bb0575], [@bb0580])*Botrytis* sp. α-pyrone derivative ([148](#p0110){ref-type="p"})/fungusPolyketide^e^Tyrosinase inhibition4.5 μMUndeterminedCHN, S. KOR([@bb1020])Cephalosporolides H and I ([149](#p0155){ref-type="p"}, [150](#p0155){ref-type="p"})/fungusPolyketide^e^Xanthine oxidase and steroid dehydr. inhib.\< 0.29 mMUndeterminedCHN, DEU([@bb0545], [@bb0550])Chaetominedione ([151](#p0110){ref-type="p"})/fungusAlkaloid^g^p56^lck^ tyrosine kinase inhibition\< 200 μg/mL^⁎^UndeterminedEGY([@bb0010])Circumdatin I ([152](#p0110){ref-type="p"})/fungusAlkaloid^g^Ultraviolet A-protecting98 μMUndeterminedS. KOR([@bb1025], [@bb1030])Diapolycopenedioic acid xylosyl ester ([153](#p0155){ref-type="p"})/bacteriumTerpenoid^f^Lipid peroxidation inhibition4.6 μMUndeterminedJPN([@bb0880])*Echinogorgia complexa* furanosesquiterpenes ([154](#p0155){ref-type="p"}, [155](#p0155){ref-type="p"})/soft coralTerpenoid^f^Mitochondrial respiratory chain inhibition2.5--4.3 μMUndeterminedESP, IND, ITA([@bb0605])19-*epi*-Okadaic acid ([156](#p0155){ref-type="p"})/dinoflagellatePolyketide^e^Protein phosphatase 2A inhibition0.47 nMUndeterminedESP([@bb0170])Erylosides F and F1 ([157](#p0155){ref-type="p"}, [158](#p0155){ref-type="p"})/coralTerpenoid^f^Activation of Ca^2+^ influx100 μg/mL^⁎^UndeterminedITA, RUS([@bb0035])*Hippocampus kuda* phthalates ([159](#p0155){ref-type="p"}, [160](#p0155){ref-type="p"}, [161](#p0155){ref-type="p"})/seahorsePolyketide^e^Cathepsin B inhibition0.18--.29 mMUndeterminedCHN, S. KOR([@bb0555], [@bb0560], [@bb0565])Irregularasulfate ([162](#p0155){ref-type="p"})/bacteriumTerpenoid^f^Calcineurin inhibition59 μMUndeterminedCAN, NLD, PAP([@bb0115])Kempopeptins A and B ([163](#p0155){ref-type="p"}, [164](#p0155){ref-type="p"})/bacteriumPeptide^g^Elastase and chymotrypsin inhibition0.32--8.4 μMUndeterminedUSA([@bb0920])Linckoside L7 ([165](#p0155){ref-type="p"})/starfishTriterpenoid glycoside^f^Fertilization inhibition\< 25 μg/mL^⁎^UndeterminedRUS([@bb0435])Lyngbyastatin 4 ([166](#p0155){ref-type="p"})/bacteriumPeptide^g^Elastase and chymotrypsin inhibition0.03--0.3 μMUndeterminedUSA([@bb0625])Malevamide E ([167](#p0155){ref-type="p"})/bacteriumPeptide^g^Extracellular Ca^2+^ channel inhibition9 μM^⁎^UndeterminedUSA([@bb0015])Monodictysin C ([168](#p0155){ref-type="p"})/fungusShikimateCYP1A inhibition3.0 μMUndeterminedDEU([@bb0485])Monodictyochromes A and B ([169](#p0155){ref-type="p"}, [170](#p0155){ref-type="p"})/fungusShikimateCYP1A inhibition5.3--7.5 μMUndeterminedDEU([@bb0815])*Penicillium waksmanii* PF1270 A, B, and C ([171](#p0155){ref-type="p"}, [172](#p0155){ref-type="p"}, [173](#p0155){ref-type="p"})/fungusAlkaloid^g^Histamine H3 receptor agonists0.12--0.2 μMUndeterminedJPN([@bb0510])*Penicillium* sp*.* anisols ([174](#p0155){ref-type="p"}, [175](#p0155){ref-type="p"}, [176](#p0155){ref-type="p"})/fungusPolyketide^e^CYP3A4 inhibition0.4--2 μg/mLUndeterminedJPN([@bb0230])*Polysiphonia urceolata* bromophenols ([177](#p0155){ref-type="p"}, [178](#p0155){ref-type="p"}, [179](#p0155){ref-type="p"}, [180](#p0155){ref-type="p"})/algaPolyketide^e^DPPH radical scavenging activity6.1--8.1 μMUndeterminedCHN([@bb0545], [@bb0550], [@bb0555], [@bb0560], [@bb0565])Pompanopeptin A ([181](#p0155){ref-type="p"})/bacteriumPeptide^g^Trypsin inhibition2.4 μMUndeterminedUSA([@bb0630])Purpurone ([182](#p0155){ref-type="p"})/spongeAlkaloid^g^DPPH radical scavenging activity7 μMUndeterminedCHN, S. KOR, USA([@bb0575], [@bb0580])Saliniketals A and B ([183](#p0155){ref-type="p"}, [184](#p0155){ref-type="p"})/bacteriumPolyketide^e^Ornithine decarboxylase induction1.9--7.8 μg/mLUndeterminedUSA([@bb0980], [@bb0985])*Sargassum sagamianum* monoglyceride ([185](#p0155){ref-type="p"})/algaPolyketide^e^Phospholipase A~2~ and COX-2 inhibitionNDUndeterminedS. KOR([@bb0120])*Sargassum siliquastrum* meroditerpenoids ([186](#p0155){ref-type="p"}, [187](#p0155){ref-type="p"}, [188](#p0155){ref-type="p"}, [189](#p0155){ref-type="p"}, [190](#p0155){ref-type="p"}, [191](#p0155){ref-type="p"})/algaTerpenoid^f^DPPH radical scavenging activity0.1--0.31 μg/mL^⁎^UndeterminedS. KOR([@bb0400])*Symphyocladia latiuscula* bromophenols ([192](#p0155){ref-type="p"}, [193](#p0155){ref-type="p"}, [194](#p0155){ref-type="p"}, [195](#p0155){ref-type="p"})/algaPolyketide^e^DPPH radical scavenging activity10.2--24 μMUndeterminedCHN([@bb0215])Tenacibactins C and D ([196](#p0155){ref-type="p"}, [197](#p0155){ref-type="p"})/bacteriumPKS/NRPSFe-binding (chelating) activity110--115 μMUndeterminedJPN([@bb0370])[^3]Fig. 3Marine compounds with miscellaneous mechanisms of action.

2. Marine compounds with antibacterial, anticoagulant, antifungal, antimalarial, antiprotozoal, antituberculosis, and antiviral activities {#s0010}
==========================================================================================================================================

[Table 1](#t0005){ref-type="table"} presents preclinical pharmacology reported during 2007--8 on the antibacterial, anticoagulant, antifungal, antimalarial, antiprotozoal, antituberculosis, and antiviral pharmacology of the marine natural products (**1** **,** **2** **,** **3** **,** **4** **,** **5** **,** **6** **,** **7** **,** **8** **,** **9** **,** **10** **,** **11** **,** **12** **,** **13** **,** **14** **,** **15** **,** **16** **,** **17** **,** **18** **,** **19** **,** **20** **,** **21** **,** **22** **,** **23** **,** **24** **,** **25** **,** **26** **,** **27** **,** **28** **,** **29** **,** **30** **,** **31** **,** **32** **,** **33** **,** **34** **,** **35** **,** **36** **,** **37** **,** **38** **,** **39** **,** **40** **,** **41** **,** **42** **,** **43** **,** **44** **,** **45** **,** **46** **,** **47** **,** **48** **,** **49** **,** **50** **,** **51** **,** **52** **,** **53** **,** **54** **,** **55** **,** **56** **,** **57** **,** **58** **,** **59** **,** **60** **,** **61** **,** **62** **,** **63** **,** **64** **,** **65** **,** **66** **,** **67** **,** **68** **,** **69** **,** **70** **,** **71** **,** **72** **,** **73** **,** **74**) shown in [Fig. 1](#f0005){ref-type="fig"}.

2.1. Antibacterial activity {#s0015}
---------------------------

Contributing to the global search for new antimicrobials to combat antibiotic-resistant strains of pathogenic bacteria, marine ecological niches have been described recently as "particularly promising" ([@bb0250]). During 2007--8, 38 studies reported novel *antibacterial* marine natural products isolated from marine bacteria, fungi, sponges, worms and fish, a larger effort than the ones reported in previous years ([@bb0695]), and previous reviews of this series.

Only six papers provided detailed mechanism of action studies with marine antimicrobial compounds. [@bb0410] reported the discovery of the novel bioactive spirodioxynaphthalene ascochytatin ([1](#p0010){ref-type="p"}) isolated from cultures of a marine-derived fungus *Ascochyta* sp. NGB4, which inhibited *B. subtilis* growth (MID = 0.3 μg/disk) by targeting the function of the bacterial growth regulatory system TCS (YycG/YycF). [@bb0455] discovered that the 120 kDa acidic glycoprotein [l]{.smallcaps}-amino acid oxidase termed SSAP ([2](#p0010){ref-type="p"}), isolated from the rockfish *Sebastes schlegelli* ([@bb0450]), acted selectively on Gram-negative bacteria (minimum inhibitory concentration (MIC) = 0.078--0.63 μg/mL). While H~2~O~2~ was shown to mediate the antibacterial action of SSAP, electron microscopy analysis revealed that SSAP induced cell surface damage and morphological changes in several bacterial species. [@bb0530], [@bb0535] reported that the 21-residue peptide arenicin-1 ([3](#p0010){ref-type="p"}) isolated from the marine polychaete *Arenicola marina* exhibited significant antibacterial activity against *P. aeruginosa* and *Staphylococcus aureus* (MIC = 2 μg/mL)*.* Interestingly, arenicin-1 induced release of calcein from PE/PG liposomes, thus suggesting that the bacterial cell membrane is the main molecular target of the peptide. [@bb0380] extended the pharmacology of the alkaloid isoaaptamine ([4](#p0010){ref-type="p"}), isolated from the marine sponge *Aaaptos aaptos*. Isoaaptamine inhibited sortase A (IC~50~  = 3.7 μg/mL), an enzyme involved in *S. aureus* cell wall protein anchoring and virulence, thus potentially providing a novel lead compound "for further development" of potent antibacterials. [@bb0540] isolated seven sesterterpenes ([5](#p0010){ref-type="p"}, [6](#p0010){ref-type="p"}, [7](#p0010){ref-type="p"}, [8](#p0010){ref-type="p"}, [9](#p0010){ref-type="p"}, [10](#p0010){ref-type="p"}, [11](#p0010){ref-type="p"}) from a tropical sponge *Dysidea* sp. which demonstrated antibacterial activity against *B. subtilis* (MIC = 1.56--12.5 μg/mL) by inhibiting isocitrate lyase activity, a key enzyme in the glyoxylate cycle which is present in most prokaryotes, lower eukaryotes and plants, but not in vertebrates. [@bb0405] described a new sulfoalkylresorcinol ([12](#p0010){ref-type="p"}) isolated from the marine-derived fungus *Zygosporium* sp. KNC52, which showed antimicrobial activity against methicillin-resistant *S. aureus.* The mechanism of action appeared to involve inhibition (IC~50~  = 12.5 μg/mL) of the *in vitro* polymerization of FtsZ, a protein which is a structural homolog of eukaryotic tubulin, and that participates in bacterial cell division.

As shown in [Table 1](#t0005){ref-type="table"}, several new marine antibacterials were also reported in 2007--8 ([Fig. 1](#f0005){ref-type="fig"}) with MICs less than 10 μg/mL against antibiotic-resistant bacterial strains, although no mechanism of action studies were reported: the alkaloids ambiguine isonitriles H and I ([13](#p0010){ref-type="p"} [14](#p0010){ref-type="p"}) isolated from a marine cyanobacterium *Fischerella* sp. ([@bb0830]); the polyketides ariakemicins A and B ([15](#p0010){ref-type="p"}, [16](#p0010){ref-type="p"}) isolated from a marine gliding bacterium *Rapidithrix* sp. ([@bb0765]); ayamycin ([17](#p0010){ref-type="p"}) isolated from a bacterium *Nocardia* sp. ALAA 2000 ([@bb0235]); the alkaloids batzelladines L and M ([18](#p0010){ref-type="p"}, [19](#p0010){ref-type="p"}) isolated from the Caribbean sponge *Monanchora unguifera* ([@bb0340]); a diphenyl ether ([20](#p0010){ref-type="p"}) isolated from the Indonesian sponge *Lamellodysidea herbacea* ([@bb0320]); essramycin ([21](#p0010){ref-type="p"}) obtained from the culture broth of a marine *Streptomyces* sp. isolate Merv8102 ([@bb0240]); a meroditerpene (+)-isojaspic acid ([22](#p0010){ref-type="p"}) isolated from the Papua New Guinean sponge *Cacospongia* sp. ([@bb0840]); the bisindole pyrroles lynamicins A--D ([23](#p0010){ref-type="p"}, [24](#p0010){ref-type="p"}, [25](#p0010){ref-type="p"}, [26](#p0010){ref-type="p"}) isolated from a novel marine actinomycete *Marinispora* sp. ([@bb0705]); lipoxazolidinones A and B ([27](#p0010){ref-type="p"}, [28](#p0010){ref-type="p"}) isolated from a marine actinomycete *Marinispora* sp. ([@bb0595]); marinopyrrole A ([29](#p0010){ref-type="p"}) isolated from an obligate marine *Streptomyces* strain ([@bb0350]); a furanosesquiterpene (--)-microcionin-1 ([30](#p0010){ref-type="p"}) isolated from a marine sponge *Fasciospongia* sp. ([@bb0280]); a macrolide phomolide B ([31](#p0010){ref-type="p"}) isolated from a fungus *Phomopsis* sp. ([@bb0210]); a sargaquinoic acid derivative ([32](#p0010){ref-type="p"}) isolated from the brown alga *Sargassum sagamianum* ([@bb0335]), and tauramamide ([33](#p0010){ref-type="p"}), a lipopeptide isolated from the bacterium *Brevibacillus laterosporus* PNG276 ([@bb0200]).

Furthermore during this period, several novel marine metabolites with moderate antimicrobial activity (MIC or IC~50~ ranging from 10 to 50 μg/mL, or 10 to 50 μM, respectively), were also reported, but their weaker antibacterial activity precluded their inclusion in either [Table 1](#t0005){ref-type="table"} or [Fig. 1](#f0005){ref-type="fig"}: acetylmajapolene A (MIC = 20 μg/disk) ([@bb0940]), callophycoic acids A, B, G and H (MIC = 16--63.9 μg/mL) ([@bb0520]); corallidictyals A, B, C and D (MIC less than 20 μg/mL) ([@bb0295]); (*S*)-(+)-curcuphenol analogs (IC~50~  = 34--44 μM) ([@bb0300]); cyclomarazines A and B (MIC = 13--18 μg/mL) ([@bb0870]); dehydroxychlorofusarielin B (MIC = 62.5 μg/mL) ([@bb0745]), nodosol (MIC = 16 μg/mL) ([@bb0475]); paeciloxanthone (MIC = 40 μg/disk) ([@bb0975]), palmitoleic acid (IC~50~  = 10--20 μM) ([@bb0195]); puupehenone-metabolites (MIC = 8--16 μg/mL) ([@bb0145]); *Tripalea clavaria* C-secosteroids (MIC = 25 μg/disk) ([@bb0835]), shishididemniols A and B (MIC = 20 μg/disk) ([@bb0470]), and zafrin (MIC = 50--125 μg/mL) ([@bb0935]).

Noteworthy were reports of novel marine antimicrobial peptides: dicentracin, a new component of the moronecidin family isolated from head kidney leukocytes from the sea bass *Dicentrarchus labrax* ([@bb0850]); hepcidins, three novel antimicrobial peptides isolated from the tilapia *Oreochromis mossambicus*, with MICs (50--100 μg/mL) against *Listeria monocytogenes*, *S. aureus*, and *Enterococcus faecium* ([@bb0345]); scygonadin, a novel anionic antimicrobial peptide from the seminal plasma of the mud crab, *Scylla serrata* ([@bb0950], [@bb0955]), and tunichromes, small dehydrodopamine-containing peptides found in hemocyte cells of the ascidian *Ascidia nigra* that are capable of crosslinking proteins *in vitro* ([@bb0100]).

2.2. Anticoagulant activity {#s0020}
---------------------------

Four articles published during 2007--8, reported *anticoagulant* marine natural products isolated from algae and clams, a number very similar to that reported in our previous review ([@bb0695]), and other reviews of this marine pharmacology series.

[@bb0395] characterized a novel 7.7 kDa anticoagulant polypeptide termed TGAP with a partial sequence ([34](#p0010){ref-type="p"}) from the muscle protein of the South Korean bivalve *Tegillarca granosa.* The anticoagulant polypeptide, which demonstrated low *in vitro* cytotoxicity to venous endothelial cells, specifically inhibited the blood coagulation factor Va, as well as the molecular interaction between factor IIa and factor Va in a concentration-dependent manner (IC~50~  = 77.9 nM), thus resulting in prolonged prothrombin time. The same research group ([@bb0390]) extended the anticoagulant pharmacology of a sulfated polysaccharide from the brown alga *E. cava.* The sulfated algal polysaccharide potently inhibited the biological activity of human blood coagulation factors IIa, VIIa and Xa in the presence of the glycoprotein antithrombin III in a dose-dependent manner (K~D~  = 15.1, 45.0 and 65.0 nM, respectively). [@bb1015] reported the purification of a complex and heterogeneous sulfated fucan from the brown alga *Laminaria cichorioides*. The purified polysaccharide had potent anticoagulant activity which resulted from enhancement of thrombin inhibition by heparin cofactor II, within the same concentration range as the clinically used heparin. [@bb0610] described two sulfated polysaccharides WF1 (870 kDa) and WF3 (70 kDa) from the marine green alga *Monostroma nitidum* which demonstrated high anticoagulant activities. Interestingly, both polysaccharides inhibited thrombin as well as potentiated antithrombin III-mediated inhibition of coagulation factor Xa.

2.3. Antifungal activity {#s0025}
------------------------

Ten studies during 2007--8 reported on the *antifungal* activity of several novel marine natural products isolated from marine algae, bacteria, sponges and sea cucumbers, a decrease from our last review ([@bb0695]), and previous reviews of this series.

As shown in [Table 1](#t0005){ref-type="table"}, only one report extended the molecular pharmacology of novel antifungal marine metabolites. [@bb0530], [@bb0535] discovered that three bromophenols ([35](#p0010){ref-type="p"}, [36](#p0010){ref-type="p"}, [37](#p0010){ref-type="p"}) isolated from the red alga *Odonthalia corymbifera* potently inhibited isocitrate lyase (ICL) (IC~50~  = 2.0--2.8 μM), an enzyme that is part of the glyoxylate cycle which is expressed during host infection by diverse pathogenic fungi. Although the investigators studied the effect of the algal bromophenols on the rice fungal pathogen *Magnaporthe grisea*, it is noteworthy that ICL has also been observed to be upregulated in *Mycobacterium tuberculosis-*infected human macrophages, and that *Candida albicans* requires ICL to be fully virulent to human hosts.

Furthermore, several marine natural products showed significant antifungal activity (i.e. MICs that were either less than 10 μg/mL, 10 μM, or 10 μg/disk) ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}; [38](#p0010){ref-type="p"}, [39](#p0010){ref-type="p"}, [40](#p0010){ref-type="p"}, [41](#p0010){ref-type="p"}, [42](#p0010){ref-type="p"}, [43](#p0010){ref-type="p"}, [44](#p0010){ref-type="p"}), although no mechanism of action studies were reported in the published articles: callipeltins J and K ([38](#p0010){ref-type="p"}, [39](#p0010){ref-type="p"}), MIC = 1 μM ([@bb0175]), the triterpene glycoside holothurin B ([40](#p0010){ref-type="p"}), MIC = 1.56 μg/mL ([@bb0495]), the macrolide neopeltolide ([41](#p0010){ref-type="p"}), MIC = 0.62 μg/mL ([@bb0995]), the cyclopeptide pedein A ([42](#p0010){ref-type="p"}), MIC = 0.6--1.6 μg/mL ([@bb0500]), and pseudoceratins A and B ([43](#p0010){ref-type="p"}, [44](#p0010){ref-type="p"}), MIC = 6.5--8.0 μg/disk ([@bb0375]). Hopefully, future studies on the molecular pharmacology of these marine compounds will elucidate their mechanisms of action.

Finally, several novel structurally characterized marine molecules isolated from sponges demonstrated MICs or IC~50~s greater than 10 μg/mL or 10 μM, and therefore, because of the reported weaker antifungal activity, they have been excluded from [Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}: eurysterols A and B (MIC = 15.6--62.5 μg/mL) ([@bb0090]); nagelamides M and N (MIC = 33.3 μg/mL) ([@bb0490]), nortetillapyrone (MIC = 31--62 μg/mL) ([@bb0960]), and *Tydemania expeditionis* triterpenoids (IC~50~  = 26--55 μM) ([@bb0385]). These marine compounds may yet provide additional pharmacological leads in the ongoing global search for clinically useful antifungal agents.

2.4. Antimalarial, antiprotozoal, and antituberculosis activity {#s0030}
---------------------------------------------------------------

As shown in [Table 1](#t0005){ref-type="table"}, during 2007--8 fourteen studies reported novel findings on the *antimalarial*, *antiprotozoal and antituberculosis* pharmacology of structurally characterized marine natural products, an increase from our previous review ([@bb0695]), and previous reviews of this series.

As shown in [Table 1](#t0005){ref-type="table"}, nine marine molecules were shown during 2007--8 to possess significant *antimalarial* activity, although mechanism of action studies were reported for only two compounds. [@bb0925] reported that (*E*)-oroidin ([45](#p0010){ref-type="p"}) and (*E*)-oroidin TFA salt ([46](#p0010){ref-type="p"}) isolated from the Turkish marine sponge *Agelas oroides* potently inhibited cultures of multidrug resistant K1 strain of *Plasmodium falciparum* (IC~50~  = 3.9 and 7.9 μg/mL, respectively) with concomitant inhibition of FabI (enoyl-ACP reductase), a key enzyme of the type II fatty acid synthase cascade (IC~50~  = 0.3 and 5.0 μg/mL, respectively). Further studies revealed that oroidin free base appeared to bind to "the enzyme--substrate complex or enzyme--cofactor complex" by an uncompetitive mechanism, providing further pharmacological characterization of the "first antimalarial marine natural product that targets *P. falciparum* FabI".

Additional antimalarial activity was reported for seven marine compounds. Two reports were contributed during 2007 by the Panama International Cooperative Biodiversity Groups project: [@bb0710] isolated a novel linear lipopeptide dragomabin ([47](#p0010){ref-type="p"}) from the cyanobacterium *Lyngbya majuscula* with moderate antimalarial activity (IC~50~  = 6.0 μM), and significant differential toxicity between the malarial parasite and mammalian cells. [@bb0570] discovered that the new cyclic hexapeptides venturamides A and B ([48](#p0010){ref-type="p"}, [49](#p0010){ref-type="p"}) isolated from a Panamanian marine cyanobacterium *Oscillatoria* sp., demonstrated significant *in vitro* antiplasmodial activity against the W2 chloroquinone-resistant strain of the parasite (IC~50~  = 5.6--8.2 μM), with mild cytotoxicity to mammalian cells, the first "example of the identification of cyanobacterial peptides with selective antimalarial activity". [@bb0420] proved that a new tetronic acid, nodulisporacid A ([50](#p0010){ref-type="p"}), from a marine-derived fungus *Nodulisporium* sp. CRIF1 isolated from a Thai soft coral, was moderately antiplasmodial (IC~50~  = 1--10 μM) against chloroquine-resistant *P. falciparum* strain 94. [@bb0720] identified a new marine *Streptomyces* sp. H668 polyether ([51](#p0010){ref-type="p"}) from Hawaii that showed *in vitro* antimalarial activity (IC~50~  = 0.1--0.2 μg/mL) against both *P. falciparum* chloroquine-susceptible (D6) and -resistant (W2) clones, with minimal cytotoxicity towards mammalian cells. [@bb0155] found that a novel acylproline derivative, tumonoic acid I ([52](#p0010){ref-type="p"}) from the Papua New Guinean marine cyanobacterium *Blennothrix cantharidosmum*, showed moderate antimalarial activity against *P. falciparum* (IC~50~  = 2 μM). [@bb0810] isolated a heterocyclic-substituted xanthone, chaetoxanthone B ([53](#p0010){ref-type="p"}) from cultures of a marine-derived fungus *Chaetomium* sp. that showed selective activity towards *P. falciparum* K1 strain (IC~50~  = 0.5 μg/mL).

Four marine compounds were reported to possess *antiprotozoal* activity. [@bb0480] re-isolated the previously reported plakortide P ([54](#p0010){ref-type="p"}) from the marine sponge *Plakortis angulospiculatus*. The compound displayed selective effects against both *Leishmania chagasi* (IC~50~  = 0.5--1.9 μg/mL) and *Trypanosoma cruzi* (IC~50~  = 2.3 μg/mL), with low concomitant hemolytic and cytotoxic activities towards human macrophages. Reportedly, the mechanism of action towards intracellular *L. chagasi* did not appear to involve nitric oxide. [@bb0885] found that two novel lipopeptides viridamides A and B ([55](#p0010){ref-type="p"}, [56](#p0010){ref-type="p"}) were nearly "equipotent" in inhibiting both *Leishmania mexicana* (IC~50~  = 1.1 μM) and *T. cruzi* (IC~50~  = 1.5 μM). Besides the antimalarial activity, [@bb0810] discovered that chaetoxanthone B ([53](#p0010){ref-type="p"}) had selective effects towards *T. cruzi* (IC~50~  = 1.5 μg/mL), with minimal cytotoxicity towards rat skeletal L6 myoblasts (IC~50~  = 47 μg/mL).

Ten new marine compounds were reported in the global search for novel *antituberculosis* agents, a considerable increase from our previous reviews ([@bb0695]), and previous reviews of this series.

[@bb0770] isolated a bioactive oxapolycyclic diterpene bipinnapterolide B ([57](#p0010){ref-type="p"}) from the Colombian gorgonian coral *Pseudopterogorgia bipinnata* which weakly inhibited growth of *M. tuberculosis* H~37~Rv (66% inhibition at 128 μg/mL). [@bb1025], [@bb1030] identified two new dimeric naphtha-*γ*-pyrones 8′-*O-*demethylnigerone ([58](#p0010){ref-type="p"}) and 8′-*O*-demethylisonigerone ([59](#p0010){ref-type="p"}) from the marine-derived fungus *Aspergillus carbonarius* which showed weak antimycobacterial activity against *M. tuberculosis* (H~37~Rv, MIC = 43 and 21.5 μM, respectively). Interestingly, the presence of conjugated C=C--C=O bonds in the pyrane ring appeared to be crucial for antifungal activity. As a result of a continued investigation of the Caribbean sea whip *Pseudopterogorgia elisabethae*, [@bb0965] reported that the novel tricarbocyclic norditerpenes caribenols A ([60](#p0010){ref-type="p"}) and B ([61](#p0010){ref-type="p"}) weakly inhibited *M. tuberculosis* (H~37~Rv, MIC = 128 and 63 μg/mL, respectively). Furthermore, [@bb0970] discovered two novel ring B abeo-sterols parguesterols A ([62](#p0010){ref-type="p"}) and B ([63](#p0010){ref-type="p"}) in the Caribbean sponge *Svenzea zeai*, which inhibited *M. tuberculosis* (H~37~Rv, MIC = 7.8 and 11.2 μg/mL, respectively). Hopefully future information on the selectivity index of these two compounds will provide additional information to support the notion that they might "constitute important lead structures for the development of novel tuberculosis drugs due to their strong activity, specificity, and low toxicity". [@bb0065] noted that several bioactive polyketides, 24-norisospiculoic acid A ([64](#p0010){ref-type="p"}), dinorspiculoic acid A ([65](#p0010){ref-type="p"}), and norspiculoic acid A ([66](#p0010){ref-type="p"}) from the Caribbean sponge *Plakortis zyggompha* also inhibited *M. tuberculosis* (H~37~Rv, MIC~99~  = 50 μg/mL). Although all of these studies demonstrate that marine terpenes and polyketides constitute potentially novel antituberculosis leads, they unfortunately did not provide detailed mechanism of action pharmacology at the time of their publication.

2.5. Antiviral activity {#s0035}
-----------------------

As shown in [Table 1](#t0005){ref-type="table"}, three reports were published on the *antiviral* pharmacology of novel marine natural products against severe acute respiratory syndrome (SARS) Corona virus, herpes simplex, and dengue virus during 2007--8. [@bb0190] discovered that the new esculetin-4-carboxylic acid ethyl ester ([67](#p0010){ref-type="p"}) from the Brazilian marine sponge *Axinella* cf. *corrugata* inhibited the SARS 3CL protease (IC~50~  = 46 μM). This is a potentially significant finding because the 3CL protease is a "high profile target" in SARS drug development as it appears to be involved in the release of replicative viral proteins as well as the RNA polymerase. [@bb0905] reported that a [d]{.smallcaps},[l]{.smallcaps}-galactan hybrid C2S-3 ([68](#p0010){ref-type="p"}) isolated from the Brazilian marine alga *Cryptonemia crenulata* showed potent antiviral activity against three clinical strains of dengue virus serotype 2 (IC~50~  = 0.8--16 μg/mL), together with low cytotoxicity. Further mechanistic work determined that C2S-3 appeared to be a "promising DENV-2 entry inhibitor". [@bb0600] described a sulfated xylomannan isolated from the Indian red seaweed *Scinaia hatei* which inhibited HSV-1 and HSV-2 (IC~50~  = 0.5--1.4 μg/mL), with low cytotoxicity, probably interfering with the HSV-1 multiplication cycle. Interestingly the "very good antiviral activity against the wide spectrum of HSV strains tested" suggested this compound might be a good candidate for further preclinical research.

Five reports contributed preclinical pharmacology of marine compounds active against the human immunodeficiency virus type-1 (HIV-1), the causative agent of the acquired immunodeficiency disease syndrome (AIDS), an increase from our previous reviews ([@bb0695]), and previous reviews of this series. [@bb0040] reported that the phlorglucinol derivative 6, 6′-bieckol ([69](#p0010){ref-type="p"}) isolated from the brown alga *E. cava* inhibited HIV-induced syncytia formation (IC~50~  = 1.72 μM), viral p24 antigen production (IC~50~  = 1.26 μM), and the activity of the HIV reverse transcriptase (IC~50~  = 1.07 μM), with "no cytotoxicity" at concentrations that inhibited HIV replication "almost completely". [@bb0150] extended the molecular pharmacology of the diterpene dolabelladienetriol ([70](#p0010){ref-type="p"}) isolated from the marine brown alga *Dictyota pfaffii.* The dolabellane diterpene blocked both synthesis and integration of the HIV-1 provirus by noncompetitively inhibiting the reverse transcriptase enzyme (K*i*  = 7.2 μM). The investigators proposed dolabelladienetriol ([70](#p0010){ref-type="p"}) as a "potential new agent for anti-HIV-1 therapy". [@bb0795] described three new depsipeptides mirabamides A, C and D ([71](#p0010){ref-type="p"}, [72](#p0010){ref-type="p"}, [73](#p0010){ref-type="p"}) isolated from the sponge *Siliquariaspongia mirabilis* that potently inhibited both HIV-1 in neutralization (IC~50~  = 0.14--0.19 μM) and HIV-1 envelope-mediated cell fusion (IC~50~  = 0.14--3.9 μM), suggesting these compounds act at an early stage of HIV-1 cell infection, "presumably through interactions with HIV-1 envelope proteins". [@bb0585] added a "novel mechanistic profiling" of the previously reported sulfated polymannuroguluronate (SPMG) ([74](#p0010){ref-type="p"}), a polysaccharide with an average molecular weight of 8.0 kDa isolated from the brown alga *Laminaria japonica*, that has been reported to be in Phase II clinical trials in China as an anti-AIDS drug candidate. SPMG appeared to eliminate the viral gene product known as transactivator of transcription protein (Tat)-induced signal transduction as well as angiogenesis in AIDS-associated Kaposi\'s sarcoma cells. Furthermore, in 2008, [@bb0360] demonstrated that SPMG appeared to show a neuroprotective effect because it decreased apoptosis caused by Tat-stimulated calcium overload in PC12 neuronal cells, thus suggesting SPMG might warrant further clinical studies in HIV-associated dementia.

3. Marine compounds with anti-inflammatory effects and affecting the immune and nervous systems {#s0040}
===============================================================================================

[Table 2](#t0010){ref-type="table"} summarizes the preclinical pharmacological research completed during 2007--8 with the marine compounds (**75** **,** **76** **,** **77** **,** **78** **,** **79** **,** **80** **,** **81** **,** **82** **,** **83** **,** **84** **,** **85** **,** **86** **,** **87** **,** **88** **,** **89** **,** **90** **,** **91** **,** **92** **,** **93** **,** **94** **,** **95** **,** **96** **,** **97** **,** **98** **,** **99** **,** **100** **,** **101** **,** **102** **,** **103** **,** **104** **,** **105** **,** **106** **,** **107** **,** **108** **,** **109** **,** **110** **,** **111** **,** **112** **,** **113** **,** **114** **,** **115** **,** **116** **,** **117** **,** **118** **,** **119** **,** **120** **,** **121** **,** **122** **,** **123** **,** **124** **,** **125** **,** **126** **,** **127** **,** **128** **,** **129** **,** **130** **,** **131** **,** **132**) shown in [Fig. 2](#f0010){ref-type="fig"}.

3.1. Anti-inflammatory marine compounds {#s0045}
---------------------------------------

The anti-inflammatory pharmacology of marine compounds reported during 2007--8 showed a considerable increase from our previous review ([@bb0695]), and previous reviews of this series. Several marine natural products were shown in preclinical pharmacological studies to target arachidonic metabolism in neutrophils and macrophages. [@bb0780] reported two new tricyclic alkaloids ascidiathiazone A ([75)](#p0110){ref-type="p"} and B ([76](#p0110){ref-type="p"}) isolated from a New Zealand ascidian *Aplidium* species that affected superoxide production by human neutrophils *in vitro* (IC~50~  = 0.44--1.55 μM), as well as murine peritoneal neutrophis *ex vivo*, with concomitant "low or nonexistent" liver and renal toxicity, thus suggesting that these two compounds might become "potential anti-inflammatory pharmaceutical" leads. [@bb0125] identified the new cembranolides crassumolides A and C ([77](#p0110){ref-type="p"}, [78](#p0110){ref-type="p"}) from the soft coral *Lobophytum crassum* which inhibited expression of iNOS and COX-2 (apparent IC~50~ less than 10 μM). Similarly, from the same university, [@bb0135] found that new cembranolides from the soft coral *Lobophytum duru*, durumolides A--C ([79](#p0110){ref-type="p"}, [80](#p0110){ref-type="p"}, [81](#p0110){ref-type="p"}) inhibited both the iNOS and COX-2 proteins in LPS-activated RAW 264.7 cells *in vitro* (apparent IC~50~ less than 10 μM), suggesting that the α-methylene-γ-lactone moiety of these compounds was necessary for the observed activity. [@bb0875] showed that new briarane-type diterpenoids frajunolides B and C ([82](#p0110){ref-type="p"}, [83](#p0110){ref-type="p"}), isolated from the Taiwanese gorgonian *Junceella fragilis*, significantly inhibited superoxide anion and elastase generation from human neutrophils *in vitro* (apparent IC~50~ greater than 10 μg/mL). [@bb0180] demonstrated that the previously described fatty acids ([84](#p0110){ref-type="p"}, [85](#p0110){ref-type="p"}) from the South Korean marine red alga *Gracilaria verrucosa* inhibited release by LPS-activated murine macrophages of the inflammatory nitric oxide, tumor necrosis factor α and interleukin-6 (apparent IC~50~ less than 20 μg/mL), thus revealing that the conjugated enone moiety played a critical role in the anti-inflammatory activity observed *in vitro.* [@bb0075] contributed novel preclinical pharmacology on a previously reported 90 amino acid polypeptide ([86](#p0110){ref-type="p"}) isolated from the red alga *Hypnea cervicornis*. The mucin-binding agglutinin, which was extensively characterized with several *in vivo* models of nociception and inflammation, probably exerted its anti-inflammatory activity (apparent IC~50~  = 0.1--1 mg/kg) via interaction of the polypeptide with the lectin carbohydrate-binding site, although the exact mechanism of action remains undetermined. [@bb0225] demonstrated that manzamine A ([87](#p0110){ref-type="p"}), (−)-8-hydroxymanzamine A ([88](#p0110){ref-type="p"}), and hexahydro-8-hydroxymanzamine A ([89)](#p0110){ref-type="p"} potently inhibited TXB~2~ generation (IC~50~  = 0.25, less than 0.1, and 1.97 μM, respectively) in brain microglia. These findings provide further support to the notion that manzamine alkaloids appear to be "viable anti-inflammatory leads" for the preclinical pharmaceutical development of agents to modulate both activated brain microglia and eicosanoid generation. [@bb0930] investigated four novel ω-3 polyunsaturated fatty acids ([90](#p0110){ref-type="p"}, [91](#p0110){ref-type="p"}, [92](#p0110){ref-type="p"}, [93](#p0110){ref-type="p"}) from the New Zealand green-lipped mussel *Perna canaliculus* with an *in vitro* bioassay that used stimulated human neutrophil 5-lipoxygenase, demonstrating that the putative anti-inflammatory potential of these compounds might be related to inhibition of leukotriene and prostaglandin metabolite production. [@bb0855] reported a bis-prenylated quinone ([94](#p0110){ref-type="p"}) from the New Zealand brown alga *Perithalia capillaris* which inhibited superoxide anion production in human neutrophils (IC~50~  = 2.1 μM) *in vitro*, with low toxicity. An explanation as to why the authors decided not to investigate the quinone "as an anti-inflammatory lead" remains unclear, although it was strongly cytotoxic towards human leukemia cells (IC~50~  = 0.34 μM). [@bb0890] characterized a novel anti-allergic phlorotannin phlorofucofuroeckol B (PFF-B) ([95](#p0110){ref-type="p"}) from the edible brown alga *Eisenia arborea*. PFF-B, inhibited β-hexosaminidase release from rat basophilic leukemia cells (IC~50~  = 7.8 μM) *in vitro*, thus showing higher potency than Tranilast (Rizaben®) (IC~50~  = 46.6 μM), a pharmaceutical agent used for treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis in Japan and South Korea. [@bb0480] demonstrated that the polyketide plakortide P ([54](#p0010){ref-type="p"}) isolated from the Brazilian sponge *P. angulospiculatus*, potently inhibited thromboxane B~2~ release (IC~50~  = 0.93 μM) from activated rat brain microglia, thus extending the preclinical pharmacology of this compound, which besides being antiparasitic as discussed earlier in this review, also appears to be a potentially "novel antineuroinflammatory agent". [@bb0785] examined a halogenated furanone rubrolide O ([96](#p0110){ref-type="p"}) isolated from a New Zealand ascidian *Synoicum* n. sp., which inhibited superoxide anion production in human neutrophils (IC~50~  = 35 μM) *in vitro* with low toxicity. Although rubrolides have been reported to be cytotoxic and antibacterial, the authors proposed that the anti-inflammatory activity for these tunicate metabolites though moderate was "unprecedented". [@bb0430] identified a *ω*-3 polyunsaturated fatty acid stearidonic acid ([97](#p0110){ref-type="p"}) from the South Korean brown seaweed *Undaria pinnatifida*, which was shown to be very active against PMA-induced mouse ear inflammation symptoms, edema, erythema and blood flows (IC~50~  = 160, 314 and 235 μg/per ear, respectively). The *in vivo* data compared well with indomethacin which was used as a positive control (IC~50~  = 90, 172, 179 μg/per ear, respectively), and thus supported claims that this "seaweed can be used as a remedy for inflammation-related symptoms". [@bb0465] discovered a novel dimeric oroidin derivative carteramine A ([98](#p0110){ref-type="p"}) in the marine sponge *Stylissa carteri*, and showed that it inhibited neutrophil chemotaxis (IC~50~  = 5 μM). The authors suggested that because carteramine A has no structural resemblance to known compounds that inhibit neutrophil chemotaxis, their finding provides a "novel platform to develop a new class of anti-inflammatory agents". [@bb0915] identified three new analogues of dolastatin 13, lyngbyastatins 5--7 ([99](#p0110){ref-type="p"}, [100](#p0110){ref-type="p"}, [101](#p0110){ref-type="p"}), isolated from marine cyanobacteria *Lyngbya* spp. from South Florida. Although the three compounds selectively and potently inhibited porcine pancreatic elastase (IC~50~  = 3--10 nM), suggesting a potential therapeutic use in pathophysiological conditions where elastase overactivity is involved, no mechanism of action studies were reported at the time. [@bb0760] purified a novel polyketide salinipyrone A ([102](#p0110){ref-type="p"}) from the marine actinomycete *Salinispora pacifica*, which moderately inhibited interleukin-5 (IC~50~  = 10 μg/mL) in a mouse splenocyte model of allergic inflammation, with low cell cytotoxicity.

3.2. Marine compounds affecting the immune system {#s0050}
-------------------------------------------------

The pharmacology of the marine compounds reporting activity on the immune system during 2007--8 showed a considerable increase from our previous review ([@bb0695]), and previous reviews of this series.

[@bb0425] investigated the red pigment cycloprodigiosin hydrochloride ([103](#p0110){ref-type="p"}) isolated from the marine bacterium *Pseudoalteromonas denitrificans*. Interestingly, the compound suppressed activator protein 1 (AP-1) (apparent IC~50~  = 1 μM), and downstream gene expression of interleukin 8, a chemokine involved in the innate immune system. [@bb0165] assessed the effect of the known compound floridoside ([104](#p0110){ref-type="p"}), isolated from the French red alga *Mastocarpus stellatus* on the complement system. Floridoside was observed to potently activate the classical complement pathway (apparent IC~50~  = 5.9--9.3 μg/mL) by recruiting immunoglobulin M (IgM), suggesting that the compound might be an "important step in the development of a potent new anticomplementary agent" useful in therapy aimed at addressing complement depletion. [@bb0290] reported that the novel iso-iantheran A and 8-carboxy-iso-iantheran A ([105](#p0110){ref-type="p"}, [106](#p0110){ref-type="p"}) purified from the Australian marine sponge *Ianthella quadrangulata* demonstrated agonist activity at P2Y~11~ receptors (IC~50~  = 1.29 and 0.48 μM, respectively). This finding represents an interesting contribution to ionotropic purine receptor P2Y~11~ pharmacology, because these receptors have been shown to affect the maturation and differentiation of dendritic cells. [@bb0355] extended the pharmacology of prodigiosin ([107](#p0110){ref-type="p"}) isolated from the marine bacterium *Hahella chejuencis* collected in South Korea. Prodigiosin inhibited iNOS mRNA expression and NO production (apparent IC~50~  = 0.1 μg/mL) by a mechanism that involved inhibition of NF-κB and p38 MAPK and JNK phosphorylation. [@bb0325] characterized the pharmacology of a water soluble polysaccharide ([108](#p0110){ref-type="p"}) isolated from the mollusc *Arca subcrenata* Lischke, a popular Chinese seafood, and named it ASLP*.* ASLP stimulated mouse spleen lymphocyte proliferation in a concentration-dependent manner (apparent IC~50~ less than 100 μg/mL), and with the "branches of ASLP" being required for the immunomodulatory bioactivity. [@bb0030] described the immunostimulant activity of frondoside A ([109](#p0110){ref-type="p"}), a triterpene glycoside isolated from the sea cucumber *Cucumaria frondosa*. The glycoside was shown to stimulate lysosomal activity and phagocytosis in mouse macrophages, as well as reactive oxygen species formation. [@bb0750] provided novel information on the molecular mechanisms affected by smenospongidine, smenospongiarine and smenospongine ([110](#p0110){ref-type="p"}, [111](#p0110){ref-type="p"}, [112](#p0110){ref-type="p"}), sesquiterpene quinones previously isolated from a Palauan marine sponge *Hippospongia* sp. The observation that at 10 μg/mL, these compounds promoted interleukin-8 release, a member of the C--X--C chemokine superfamily which is involved in tumor progression and metastasis, suggested that "the functional group at C-18" might play a yet undetermined role in the observed results. [@bb1010] isolated the novel macrosphelide M ([113](#p0110){ref-type="p"}) and peribysin J ([114](#p0110){ref-type="p"}) from *Periconia byssoides*, a fungal strain discovered from the sea hare *Aplysia kurodai*. Significantly, both fungal metabolites inhibited the adhesion of human promyelocytic leukemia HL-60 cells to human umbilical vein endothelial cells (IC~50~  = 33.2 and 11.8 μM, respectively) more potently than herbimycin A (IC~50~  = 38 μM). The latter compound, a benzochinoid ansamycin antibiotic isolated from *Streptomyces* sp. was used as a positive control in these studies. [@bb0590] contributed a novel cembranolide querciformolide C ([115](#p0110){ref-type="p"}) from the soft coral *Sinularia querciformis*, which significantly inhibited the activation of the iNOS and COX-2 enzymes (apparent IC~50~ less than 10 μM) in LPS-activated murine macrophages *in vitro*. [@bb0805] discovered that new diterpenoids ([116](#p0110){ref-type="p"}, [117](#p0110){ref-type="p"}) isolated from a Northern Cook Islands marine sponge *Spongia* (*Heterofibria*) sp. moderately activated murine splenocytes lysosomes (apparent IC~50~ greater than 100 μg/mL). [@bb0755] characterized a novel cyclic peptide thalassospiramide B ([118](#p0110){ref-type="p"}) isolated from a marine bacterium *Thalassospira* sp., which showed immunosuppressive activity in an interleukin-5 (IL-5) inhibition assay (IC~50~  = 5 μM); an interesting finding because IL-5 is expressed both in eosinophils and mast cells in asthmatic patients.

3.3. Marine compounds affecting the nervous system {#s0055}
--------------------------------------------------

Pharmacological studies with marine compounds affecting the nervous system involved three areas of neuropharmacology: the stimulation of neurogenesis, the targeting of receptors, and other miscellaneous activities on the nervous system.

Marine natural products reported to be neuritogenic, might be used to treat damaged neuronal cells, and potentially neurodegenerative diseases. As shown in [Table 2](#t0010){ref-type="table"}, compounds ([119](#p0110){ref-type="p"}, [120](#p0110){ref-type="p"}, [121](#p0110){ref-type="p"}, [122](#p0110){ref-type="p"}, [123](#p0110){ref-type="p"}, [124](#p0110){ref-type="p"}, [125](#p0110){ref-type="p"}, [126](#p0110){ref-type="p"}) isolated from sea stars and a brown alga were observed to enhance the neuritogenic properties of nerve growth factor (NGF), a compound that has a critical role in differentiation, survival, and neuronal regeneration.

[@bb0440] contributed two new steroid glycosides, linckosides L1 ([119](#p0110){ref-type="p"}) and L2 ([120](#p0110){ref-type="p"}) isolated from the Vietnamese blue sea star *Linckia laevigata*. All three glycosides (apparent IC~50~  = 0.3 μM) showed synergistic effects on NGF-induced (2 ng/mL) neurite outgrowth of murine neuroblastoma C-1300 cells. [@bb0315] contributed the novel steroid glycosides linckosides M--Q ([121](#p0110){ref-type="p"}, [122](#p0110){ref-type="p"}, [123](#p0110){ref-type="p"}, [124](#p0110){ref-type="p"}, [125](#p0110){ref-type="p"}) from the Japanese sea star *L. laevigata.* Linckoside P ([124](#p0110){ref-type="p"}) induced neurite outgrowth in 55% of rat pheochromocytoma PC12 cells at 10 μM in the presence of nerve growth factor (NGF), while linckosides M--O appeared less active (21--32%), suggesting the importance of "the xylose on a side chain". [@bb0365] characterized pheophytin A ([126](#p0110){ref-type="p"}) purified from the Japanese brown alga *Sargassum fulvellum* as a novel neurodifferentiation compound. Pheophytin A at 3.9 μg/mL was observed to synergize with NGF (50 ng/mL) in promoting neurite outgrowth in rat pheochromocytoma PC12 cells by a mechanism that appeared to involve activation of mitogen-activated protein kinase signaling.

As shown in [Table 2](#t0010){ref-type="table"}, during 2007--8, three marine compounds ([127](#p0110){ref-type="p"}, [128](#p0110){ref-type="p"}, [129](#p0110){ref-type="p"}) were reported to target receptors in the nervous system. [@bb0790] reported on the preclinical pharmacology of the α4/7-conotoxin Lp1.1 ([127](#p0110){ref-type="p"}) originally isolated from the marine cone snail *Conus leopardus*. The conotoxin induced seizure and paralysis in goldfish, and selectively yet reversibly inhibited acetylcholine-evoked currents in *Xenopus* oocytes expressing rat α6α3β2 and α3β2 nicotinic receptors (apparent IC~50~ less than 10 μM). [@bb0025] characterized two novel bromopyrrole alkaloids damipipecolin ([128](#p0110){ref-type="p"}) and damituricin ([129](#p0110){ref-type="p"}) isolated from the Mediterranean sponge *Axinella damicornis* that were observed to modulate serotonin receptor activity *in vitro*. Although damipipecolin inhibited Ca^2+^ entry in neurons (apparent IC~50~  = 1 μg/mL), the serotonin receptor subtype involved in the mechanism of action remains undetermined.

Finally, as shown in [Table 2](#t0010){ref-type="table"}, during 2007--8, additional marine compounds ([74](#p0010){ref-type="p"} and [130](#p0110){ref-type="p"}, [131](#p0110){ref-type="p"}, [132](#p0110){ref-type="p"}) were reported to have miscellaneous effects on components of the nervous system. Contributing to the ongoing search for acetylcholinesterase inhibitors useful in the treatment of Alzheimer\'s disease, [@bb0525] reported a new stigmastane-type steroidal alkaloid 4-acetoxy-plakinamine B ([130](#p0110){ref-type="p"}), isolated from a Thai marine sponge *Corticium* sp. that significantly inhibited acetylcholinesterase (IC~50~  = 3.75 μM). Compound [130](#p0110){ref-type="p"} was reported to be the "first marine-derived acetylcholinesterase-inhibiting steroidal alkaloid" with a mechanism of action involving an unusual mixed-competitive mode of inhibition. [@bb0140] extended the molecular pharmacology of two known meroditerpenes, sargaquinoic acid ([131](#p0110){ref-type="p"}) and sargachromenol ([132](#p0110){ref-type="p"}) isolated from the brown alga *S. sagamianum.* Sargaquinoic acid potently inhibited butyrylcholinesterase (IC~50~  = 26 nM), a novel target for the treatment of Alzheimer\'s disease, with potency comparable to or greater than anticholinesterases in current clinical use*.* [@bb0360] further characterized the neuroprotective effects of the polysaccharide sulfated polymannuroguluronate (SPMG) ([74](#p0010){ref-type="p"}), noted earlier as currently being in Phase II clinical trials in China as an anti-AIDS drug candidate. SPMG appeared to decrease the Tat-stimulated calcium overload in PC12 neuronal cells as well as concomitant apoptosis-signaling cascades, thus demonstrating a potential for further clinical development as a therapeutic intervention in HIV-associated dementia.

4. Marine compounds with miscellaneous mechanisms of action {#s0060}
===========================================================

[Table 3](#t0015){ref-type="table"} lists 65 marine compounds with miscellaneous pharmacological mechanisms of action, and their respective structures (**133** **,** **134** **,** **135** **,** **136** **,** **137** **,** **138** **,** **139** **,** **140** **,** **141** **,** **142** **,** **143** **,** **144** **,** **145** **,** **146** **,** **147** **,** **148** **,** **149** **,** **150** **,** **151** **,** **152** **,** **153** **,** **154** **,** **155** **,** **156** **,** **157** **,** **158** **,** **159** **,** **160** **,** **161** **,** **162** **,** **163** **,** **164** **,** **165** **,** **166** **,** **167** **,** **168** **,** **169** **,** **170** **,** **171** **,** **172** **,** **173** **,** **174** **,** **175** **,** **176** **,** **177** **,** **178** **,** **179** **,** **180** **,** **181** **,** **182** **,** **183** **,** **184** **,** **185** **,** **186** **,** **187** **,** **188** **,** **189** **,** **190** **,** **191** **,** **192** **,** **193** **,** **194** **,** **195** **,** **196** **,** **197**) are presented in [Fig. 3](#f0015){ref-type="fig"}. Because during 2007--8 additional pharmacological data were unavailable, it was not possible to assign these marine compounds to a particular drug class as was possible with the compounds included in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.

[Table 3](#t0015){ref-type="table"} shows 14 marine natural products that the peer-reviewed literature reported with a pharmacological activity, an IC~50~, and a molecular mechanism of action affected by the respective compound: azumamide E ([133](#p0155){ref-type="p"}), 1-deoxyrubralactone ([134](#p0155){ref-type="p"}), fucoxanthin ([135)](#p0155){ref-type="p"}, okadaic acid ([136](#p0155){ref-type="p"}), saproxanthin and myxol ([137](#p0155){ref-type="p"}, [138](#p0155){ref-type="p"}), sarcomilasterol ([139](#p0155){ref-type="p"}), spirastrellolides C, D, and E ([140](#p0155){ref-type="p"}, [141](#p0155){ref-type="p"}, [142](#p0155){ref-type="p"}), *Spongia* sesterterpenoid ([143](#p0155){ref-type="p"}), stylissadines A and B ([144](#p0155){ref-type="p"}, [145](#p0155){ref-type="p"}) and symbiodinolide ([146](#p0155){ref-type="p"}).

In contrast, although a pharmacological activity was described, and an IC~50~ for inhibition of an enzyme or receptor determined, detailed molecular mechanism of action studies were unavailable at the time of publication for the following 51 marine compounds included in [Table 3](#t0015){ref-type="table"}: *Asterias amurensis* saponin ([147](#p0155){ref-type="p"}), *Botrytis* sp. α-pyrone derivative ([148](#p0155){ref-type="p"}), cephalosporolides H and I ([149](#p0155){ref-type="p"}, [150](#p0155){ref-type="p"}), chaetominedione ([151](#p0155){ref-type="p"}), circumdatin I ([152](#p0155){ref-type="p"}), diapolycopenedioic acid xylosyl ester ([153](#p0155){ref-type="p"}), *Echinogorgia complexa* furanosesquiterpenes ([154](#p0155){ref-type="p"}, [155](#p0155){ref-type="p"}), 19-*epi*-okadaic acid ([156](#p0155){ref-type="p"}), erylosides F and F~1~ ([157](#p0155){ref-type="p"}, [158](#p0155){ref-type="p"}), *Hippocampus kuda* phthalates ([159](#p0155){ref-type="p"}, [160](#p0155){ref-type="p"}, [161](#p0155){ref-type="p"}), irregularasulfate ([162](#p0155){ref-type="p"}), kempopeptins A and B ([163](#p0155){ref-type="p"}, [164](#p0155){ref-type="p"}), linckoside L7 ([165](#p0155){ref-type="p"}), lyngbyastatin 4 ([166](#p0155){ref-type="p"}), malevamide E ([167](#p0155){ref-type="p"}), monodictysin C ([168](#p0155){ref-type="p"}), monodictyochromes A and B ([169](#p0155){ref-type="p"}, [170](#p0155){ref-type="p"}), *Penicillium waksmanii* PF1270 A, B, and C ([171](#p0155){ref-type="p"}, [172](#p0155){ref-type="p"}, [173](#p0155){ref-type="p"}), *Penicillium* sp*.* anisols ([174](#p0155){ref-type="p"}, [175](#p0155){ref-type="p"}, [176](#p0155){ref-type="p"}), *Polysiphonia urceolata* bromophenols ([177](#p0155){ref-type="p"}, [178](#p0155){ref-type="p"}, [179](#p0155){ref-type="p"}, [180](#p0155){ref-type="p"}), pompanopeptin A ([181](#p0155){ref-type="p"}), purpurone ([182](#p0155){ref-type="p"}), saliniketals A and B ([183](#p0155){ref-type="p"}, [184](#p0155){ref-type="p"}), *S. sagamianum* monoglyceride ([185](#p0155){ref-type="p"}), *Sargassum siliquastrum* meroditerpenoids ([186](#p0155){ref-type="p"}, [187](#p0155){ref-type="p"}, [188](#p0155){ref-type="p"}, [189](#p0155){ref-type="p"}, [190](#p0155){ref-type="p"}, [191](#p0155){ref-type="p"}), *Symphyocladia latiuscula* bromophenols ([192](#p0155){ref-type="p"}, [193](#p0155){ref-type="p"}, [194](#p0155){ref-type="p"}, [195](#p0155){ref-type="p"}), and tenacibactins C and D ([196](#p0155){ref-type="p"}, [197](#p0155){ref-type="p"}).

5. Reviews on marine pharmacology {#s0065}
=================================

Several reviews covering both general and specific subject areas of marine pharmacology were published during 2007--8: (a) *general marine pharmacology*: marine natural products with an emphasis on source organisms and relevant biological activities ([@bb0080], [@bb0085]); the value of natural products to future pharmaceutical discovery ([@bb0050]); the structures and bioactivities of secondary metabolites from cyanobacteria ([@bb0275]); bioactive natural products from marine cyanobacteria for drug discovery ([@bb0910]); bioactive compounds from fungi in the South China Sea ([@bb0775]); biochemical and pharmacological functions of β-carboline alkaloids ([@bb0105]); pharmacological properties of lamellarin alkaloids ([@bb0460]); biological activity of brown seaweed fucoidans ([@bb0505], [@bb0555]); potential pharmacological uses of the marine green alga polysaccharide ulvan ([@bb0515]); pharmacological properties of marine bis- and tris-indole alkaloids ([@bb0305]); (b) *antimicrobial marine pharmacology*: a renaissance of genomics in antibacterial discovery from actinomycetes ([@bb0055]); mining marine genomics for novel drug discovery from phytosymbionts of marine invertebrates ([@bb0220]); (c) *anticoagulant and cardiovascular pharmacology*: structure, biology, evolution and medical importance of sulfated fucans and galactans as potential antithrombotic compounds ([@bb0800]); (d) *antituberculosis*, *antimalarial and antifungal marine pharmacology*: natural product growth inhibitors of *Mycobacterium tuberculosis* ([@bb0160]); new advances in novel marine fatty acids as antimalarials, antimycobacterial and antifungal agents ([@bb0110]); depsipeptides from microorganisms as a new class of antimalarials ([@bb0265]); the manzamine alkaloids for the control of malaria and tuberculosis ([@bb0310]); (e) *immuno- and anti-inflammatory marine pharmacology*: chemistry and biology of anti-inflammatory marine natural products ([@bb0005]); marine natural products as targeted modulators of the transcription factor NF-κB ([@bb0260]); glycolipids as immunostimulating agents ([@bb1000]); (f) *nervous system marine pharmacology*: marine-derived drugs in neurology ([@bb0615]); neuritogenic gangliosides from marine echinoderms ([@bb0330]); (g) *miscellaneous molecular targets*: enzyme inhibitors from marine invertebrates ([@bb0735]); natural products as aromatase inhibitors ([@bb0060]); biology of the aeruginosin family of serine protease inhibitors ([@bb0245]); and marine natural products affecting membrane and intracellular processes, and ion channels ([@bb0255]).

6. Conclusion {#s0070}
=============

Six years after the approval of the marine compound ziconotide (Prialt®) by the U.S. Food and Drug Administration ([@bb0990]), the global marine preclinical pharmaceutical pipeline remains very active. The marine pharmaceutical clinical pipeline is available at <http://marinepharmacology.midwestern.edu/clinDev.htm> and has recently been reviewed ([@bb0700]).

The current marine preclinical pipeline review contributes to the annual review series which was initiated in 1998 ([@bb0680], [@bb0665], [@bb0670], [@bb0675], [@bb0690], [@bb0695]) and reveals the breadth of preclinical pharmacological research during 2007--8, which resulted from the global effort of natural products chemists and pharmacologists from Argentina, Australia, Brazil, Canada, China, Egypt, France, Germany, India, Israel, Italy, Japan, the Netherlands, New Zealand, Panama, Papua New Guinea, Portugal, Russia, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, Vietnam, and the United States. Thus, it appears that the marine preclinical pharmaceutical pipeline continues to contribute novel pharmacological lead compounds that will probably enable a future expansion of the marine clinical pharmaceutical pipeline, which currently consists of 13 compounds in Phase I, II and III of clinical development ([@bb0700]).
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[^1]: ^a^Organism, *Kingdom Animalia*: polychaeta (Phylum Annelida), rockfish (Phylum Chordata), corals (Phylum Cnidaria), sea cucumber (Phylum Echinodermata), bivalve (Phylum Mollusca), sponge (Phylum Porifera); *Kingdom Monera*: bacterium (Phylum Cyanobacteria); *Kingdom Fungi*: fungus; *Kingdom Plantae*: alga; ^b^IC~50~: concentration of a compound required for 50% inhibition *in vitro*; \*: estimated IC~50~, ND: not determined; ^+^MIC: minimum inhibitory concentration; ^++^MID: minimum inhibitory concentration per disk; ^+++^MIC~90~: minimum inhibitory concentration; ^b^MMOA: molecular mechanism of action; ^c^Country: ARG: Argentina; BRA: Brazil; CAN: Canada; CHE: Switzerland; CHN: China; EGY: Egypt; ESP: Spain; FRA: France; DEU: Germany; GBR: United Kingdom; IND: India; ISR: Israel; ITA: Italy; JPN: Japan; NLD: The Netherlands; NZL: New Zealand; PAN: Panama; PAP: Papua New Guinea; PRT: Portugal; S. KOR: South Korea; THAI: Thailand; TUR: Turkey; Chemistry: ^d^polyketide; ^e^terpene; ^f^nitrogen-containing compound; ^g^polysaccharide, modified as in the text.

[^2]: ^a^Organism: *Kingdom Animalia*: coral (Phylum Cnidaria); ascidian (Phylum Chordata), sea star, cucumber (Phylum Echinodermata); clam, musse, snail (Phylum Mollusca); sponge (Phylum Porifera); *Kingdom Fungi*: fungus; *Kingdom Plantae*: alga; *Kingdom Monera*: bacterium (Phylum Cyanobacteria); ^b^IC~50~: concentration of a compound required for 50% inhibition; \*: apparent IC~50~; ND: not determined; ^c^MMOA: molecular mechanism of action, NO: nitric oxide; ^d^Country: AUS: Australia; BRA: Brazil; CHN: China; DEU: Germany; FRA: France; ITA: Italy; JPN: Japan; NZL: New Zealand; RUS: Russia; S. KOR: South Korea; TAIW: Taiwan; THAI: Thailand; Chemistry: ^e^polyketide; ^f^terpene; ^g^nitrogen-containing compound; ^h^polysaccharide, modified as in the text.

[^3]: ^a^Organism, *Kingdom Animalia*: sea horse (Phylum Chordata), soft corals (Phylum Cnidaria), starfish (Phylum Echinodermata), sponge (Phylum Porifera); *Kingdom Chromalveolata*: dinoflagellates; *Kingdom Fungi*: fungus; *Kingdom Plantae*: alga; *Kingdom Monera*: bacterium; ^b^IC~50~: concentration of a compound required for 50% inhibition *in vitro*; \*: estimated IC~50~; \*\* Kd: concentration at which 50% of ligand binding sites are occupied; MMOA: molecular mechanism of action ;^d^Country: CAN: Canada; CHN: China; EGY: Egypt; ESP: Spain; DEU: Germany; IND: India; ITA: Italy; JPN: Japan; NLD: The Netherlands; PAP: Papua New Guinea; RUS: Russia; S. KOR: South Korea; VNM: Vietnam. Chemistry: ^e^polyketide; ^f^terpene; ^g^nitrogen-containing compound; ^h^polysaccharide, modified as in the text.
